Patents Examined by Kristin Vajda
  • Substituted cyanophosphine additives for lithium conducting carbon phosphonitrides
    Patent number: 11780860
    Abstract: Cyanophosphines other than P(CN)3 react with lithium dicyanamide to produce lithiated carbon phosphonitrides with mobile Li+ ions.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: October 10, 2023
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Brian L. Chaloux, Andrew P. Purdy, Albert Epshteyn
  • Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
    Patent number: 11780858
    Abstract: The invention provides novel pyridinamine-pyridone and pyrimidinamine-pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections; wherein R1, R2, R3 and Z are as defined in the specification.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: October 10, 2023
    Assignee: Sprint Bioscience AB
    Inventors: Johan Lindström, Rickard Forsblom, Tobias Ginman, Fredrik Rahm, Jenny Viklund
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11773105
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: October 3, 2023
    Assignee: AbbVie Inc.
    Inventor: Ayman Allian
  • Disinfecting composition
    Patent number: 11771082
    Abstract: A disinfecting composition for killing pathogens on various surfaces is provided. The disinfecting composition is environmentally friendly and is certified natural according to the ECOCERT certification for detergents. The disinfecting composition generally includes one or more C1-8 alcohols and at least three surfactants. The disinfecting composition passes one or more of the following European standards at a contact time of less than or equal to about 1 minute: EN 13697, EN 13727, EN 1275, EN 1650, and EN 13624.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: October 3, 2023
    Assignee: GOJO Industries, Inc.
    Inventors: Elodie Greboval, Kamel El Yacoubi, Anne Matsuda, Magali Moreau, Johanna Torest
  • Methods of making high enantioselective secondary alcohols
    Patent number: 11773118
    Abstract: A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: October 3, 2023
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Yih-Huang Hsieh, Shu-Yi Lin, Chin-Sheng Chao, Yin-Cheng Hsieh, Ming-Tain Lai
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11767326
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: September 26, 2023
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Methods and compositions for targeting PD-L1
    Patent number: 11760764
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: September 19, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
  • Compositions of matter and pharmaceutical compositions
    Patent number: 11759452
    Abstract: Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: September 19, 2023
    Assignee: Psilera Inc.
    Inventors: Christopher G. Witowski, Jacqueline L. Salm
  • Compounds and compositions for inducing chondrogenesis
    Patent number: 11753416
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: September 12, 2023
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
  • LXR inverse agonists for treatment of cancer
    Patent number: 11746097
    Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 5, 2023
    Assignee: Saint Louis University
    Inventors: Thomas Burris, John K. Walker, Colin Flaveny, Arindam Chatterjee
  • Methods and pharmaceutical preparations for elevating blood hemoglobin and oxygen saturation levels with hydroxycitric acid
    Patent number: 11744814
    Abstract: Provided is a method of treating a subject, including: (i) determining an initial level of blood oxygen saturation in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, wherein HCA is (?)-hydroxycitric acid, a salt thereof, or a derivative thereof, thereby increasing blood oxygen saturation. Provided is a kit including HCA and instructions directing a subject to ingest the HCA if the subject is determined to have unhealthily low blood oxygen saturation. Provided is a method of treating a subject, including: (i) determining an initial level of blood hemoglobin in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, thereby increasing blood hemoglobin.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: September 5, 2023
    Assignee: GLYKON TECHNOLOGIES GROUP, LLC
    Inventor: Daniel E. Clouatre
  • Fused pyrimidine compounds as KRAS inhibitors
    Patent number: 11739102
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: August 29, 2023
    Assignee: INCYTE CORPORATION
    Inventors: Gia Hoang, Xiaozhao Wang, Wenqing Yao
  • Treating and preventing motor neuron diseases using nicotinamide riboside
    Patent number: 11730751
    Abstract: Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 22, 2023
    Assignees: UNIVERSITAT DE VALÈNCIA-ESTUDI GENERAL, FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR, Elysium Health, Inc.
    Inventors: José Maria Estrela Ariguel, José Enrique De La Rubia Orti, Ryan Dellinger
  • Preparation method of a cyclic phosphonate compound
    Patent number: 11725019
    Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: August 15, 2023
    Assignee: GANNEX PHARMA CO LTD.
    Inventors: Jinzi J. Wu, Bailing Yang, Bin Liang
  • Hydroxynorketamine for the use in the treatment of depression
    Patent number: 11723883
    Abstract: The present invention relates to hydroxynorketamine for the use in the treatment of depression. In particular, the present invention concerns hydroxynorketamine for use in the treatment of depression, wherein hydroxynorketamine is administered in form of at least one prodrug, and wherein the at least one prodrug is orally administered in a modified-release dosage form. The prodrug is selected from (S)-Ketamine, (R)-Ketamine, (R,S)-Ketamine, (S)-Norketamine, (R)-Norketamine, (R,S)-Norketamine, (S)-Hydroxyketamine, (R)-Hydroxyketamine, (R,S)-Hydroxyketamine.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 15, 2023
    Assignee: Ketabon GmbH
    Inventor: Helene Rey
  • IRAK degraders and uses thereof
    Patent number: 11723980
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: August 15, 2023
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang
  • 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
    Patent number: 11718588
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: August 8, 2023
    Assignee: GALAPAGOS NV
    Inventors: Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11718627
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: August 8, 2023
    Assignee: AbbVie Inc.
    Inventor: Ayman Allian
  • Compositions and methods of treating neuronal injury
    Patent number: 11712444
    Abstract: The present invention features methods and composition directed to treating neuronal injury, CNS lesion, and/or promoting axon regeneration using a phosphine sulfide-stabilized phosphine.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 1, 2023
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, GEORGIA TECH RESEARCH CORPORATION
    Inventors: Elena G. Sergeeva, Paul A. Rosenberg, Larry I. Benowitz, Christoph J. Fahrni, Michael Thomas Morgan
  • Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
    Patent number: 11708351
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: July 25, 2023
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman